Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Osteoporos Int. 2019 Oct 12;31(1):67–75. doi: 10.1007/s00198-019-05142-z

Figure 3.

Figure 3

a: Anti-osteoporosis medication (AOM) adherence over the 5 year duration of the SCOOP trial in study participants who initiated treatment, and who had not experienced a fracture between baseline and commencement of medication. (Calculated as the percent study participants who remained on AOM at each subsequent timepoint having initiated treatment at each index timepoint.)

b: Anti-osteoporosis medication (AOM) adherence over the 5 year duration of the SCOOP trial in study participants who initiated treatment after the occurrence of a fracture post-baseline. (Calculated as the percent study participants who remained on AOM at each subsequent timepoint having initiated treatment at each index timepoint.)